Palido 3

Paliperidone 3mg

-PALIDO (Paliperidone) is the active metabolite of risperidone,
-PALIDO is a centrally active dopamine D2 antagonist with predominant serotonergic 5-HT2A
antagonistic activity.
-PALIDO has weaker affinity for α1 and α2 adrenergic receptors, which may
contribute to fewer adverse events than observed with risperidone
-Paliperidone has no relevant affinity toward muscarinic receptors, resulting in the
absence of anticholinergic side effects.
-PALIDO undergoes limited hepatic metabolism, thereby minimizing the risks of
hepatic drug–drug and drug–disease interactions.
-Compared to IR risperidone, Palido ER leads to lower incidences of orthostatic
hypotension and allows for initiation of treatment at an effective dose without titration.
-Paliperidone ER has a more favorable adverse event profile than risperidone
regarding extrapyramidal and prolactin-increasing effects.